Larvol Delta - A-Phase-3-Clinical-Protocol-PlaceboControlled-DoubleBlind-ParallelGroup-to-Evaluate-Safety-and-Efficacy-of-NA831-as-Monotherapy-and-in-Combination-with-Donanemab-in-Subjects-with-Early-Alzheimer39s-Disease

traneurocin oral (NA-831) - Biomed Industries

Kisunla (donanemab-azbt) - Eli Lilly

https://www.ctad-alzheimer.com/sites/www.ctad-alzheimer.com/files/medias/documents/Poster%20list_0112.pdf

Lloyd TRAN; Fern VU; Zung TRAN

Dec 14, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next